Revision history of "Time stability studies of biotechnological medicines — monoclonal antibodies and fusion proteins -. Comprehensive conformational studies." (Q3161520)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

7 March 2024

20 December 2023

12 June 2023

10 June 2023

4 August 2022

  • curprev 09:2009:20, 4 August 2022DG Regio talk contribs 74,523 bytes +51,214 Changed label, description and/or aliases in et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv, nl, fr, de, it, es, and other parts: Adding translations: et, lt, hr, el, sk, fi, pl, hu, cs, lv, ga, sl, bg, mt, pt, da, ro, sv,

16 January 2022

17 December 2021

9 December 2021

4 December 2021

12 October 2021

  • curprev 17:0817:08, 12 October 2021DG Regio talk contribs 12,693 bytes +199 Changed label, description and/or aliases in en: translated_label
  • curprev 17:0817:08, 12 October 2021DG Regio talk contribs 12,494 bytes +2,290 Created claim: summary (P836): The use of therapeutic proteins such as monoclonal antibodies and fusion proteins is currently consolidated in the treatment of diseases of high prevalence (cancer and autoimmune diseases), mainly of hospital use. These biotechnological medicines have in common their high price, which translates into the greatest impact on hospital pharmaceutical spending. The stability studies of the pharmaceutical industry are aimed at meeting the marketing re...

10 October 2021

9 October 2021

8 October 2021